News & Sentiment
$15M Investment to Launch High Tech Ice Manufacturing Facility in Oak Park - 50 New Jobs
Motor City Ice repurposes former 30,000-square-foot Forgotten Harvest building into a fully automated ice production facility serving Metro Detroit. DETROIT, Oct. 27, 2026 /PRNewswire/ -- A group of three established Metro Detroit business families has invested more than $15 million to...
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
717 articles
📰
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.
📰
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.
📰
HCA (HCA) Q3 2026 Earnings Call Transcript
Volume growth hit 22 consecutive quarters, but payer mix shifts cost $400M in EBITDA.
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin...
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin...
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin...
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin...
📰
Centene (CNC) Q3 2026 Earnings Call Transcript
Medicare Advantage reaches breakeven ahead of schedule as Medicaid membership declines.
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and...
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and...
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and...
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and...
📰
HCA (HCA) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for HCA (HCA) give a sense of how its business performed in the quarter ended September 2026, it might be worth...
📰
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.
📰
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.
Gilead to Report Q3 Earnings: How Should You Play the Stock Now?
Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant...
Gilead to Report Q3 Earnings: How Should You Play the Stock Now?
Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant...
Gilead to Report Q3 Earnings: How Should You Play the Stock Now?
Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant...
📰
AMN vs. TRI: Which Stock Is the Better Value Option?
AMN vs. TRI: Which Stock Is the Better Value Option?
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise...
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise...
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise...
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise...
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.